A 77-year-old Asian man with congenital lymphedema had been diagnosed with JAK2-V617F mutation positive primary myelofibrosis for 2 years. After diagnosis, he was treated with hydroxyurea 500 mg/day. The patient has developed palmoplantar hyperpigmentation after receiving 22 months of hydroxyurea therapy (Fig. 1 ).
Hydroxyurea is a well-tolerated drug but can cause mucocutaneous side effects including hyperpigmentation of the skin, nails, and mucous membrane; and ulcer of the legs. The hyperpigmentation has been reported to occur between 2 weeks and 2 years [1, 2] . It is usually persistent for several months and seldom permanent after discontinuation of medication [2] . 
